Number of UK trial contracts collapses ahead of Brexit

4 September 2018

The UK has long been considered an attractive place to hold trials to test new medicines, but not any more.

According to an article in The Guardian, the European Medicines Agency (EMA) is cutting the UK out of new contracts for research and reallocating existing ones to European Union (EU) members, as the UK is set to leave the bloc in March 2019.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has built up a close relationship over a number of years with the EMA, which has been based in London but is moving operations to Amsterdam due to Brexit.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK